Ortho Clinical Diagnostics [TOP]

Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing. Ortho serves two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood.[3]

Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. Ortho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York.

Ortho produces in-vitro diagnostics equipment and associated assays and reagents, serving the clinical laboratories and immunohematology sectors of the medical field.[15]

Ortho sells its products in more than 125 countries and is targeting emerging markets for future growth.[2]

Ortho Clinical Diagnostics

DOWNLOAD 🔥 https://urllio.com/2y3yBu 🔥

Background: As more companies obtain regulatory approval for high-sensitivity cardiac troponin (hs-cTn) assays there is an urgent need for independent analytical and clinical evaluations. To this end, we have evaluated Ortho Clinical Diagnostics' hs-cTnI assay and compared it to their contemporary cTnI-ES assay in emergency department (ED) patients with suspected acute coronary syndrome (ACS).

Ortho-Clinical Diagnostics, Inc. (Ortho), of Rochester, New York, protests the award of a contract to Beckman Coulter, Inc., of Brea, California, under request for quotations (RFQ) No. N6264520R0004, issued by the Department of the Navy, Naval Medical Logistics Command for two clinical chemistry/immunoassay laboratory analyzer systems and one laboratory automation system, to provide laboratory testing of patient specimens at the Naval hospital in Jacksonville, Florida. Ortho contends that the agency unreasonably evaluated its quotation and failed to conduct meaningful discussions.

Dr. Madaus, who assumes his leadership roles at OCD beginning today, has more than 25 years of experience in the diagnostics and life science industries, and a consistent track record of growing businesses. Dr. Madaus was most recently Executive Chairman of the Quanterix Board of Directors and previously served as President, Chairman and Chief Executive Officer of Millipore Corp. Before joining Millipore, Dr. Madaus was President, Chief Executive Officer and Head of North American Operations for Roche Diagnostics Corp.

About Ortho-Clinical Diagnostics, Inc.

Ortho-Clinical Diagnostics, Inc. delivers the high-quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho-Clinical Diagnostics, Inc. also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit www.orthoclinical.com

Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For more than 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes, offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, microbiology, automation and information systems. Beckman Coulter is dedicated to advancing healthcare for every person. For more information, visit www.beckmancoulter.com.

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 120 countries, Ortho's high-quality products and services enable healthcare professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

RARITAN, N.J., Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its initial public offering of 76 million ordinary shares at $17.00 per share. The gross proceeds raised from this offering are expected to be $1,292 million. Ortho's ordinary shares are expected to begin trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX," and the offering is expected to close on February 1, 2021, subject to customary closing conditions.

As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, we proudly serve the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.

Ortho Clinical Diagnostics Holdings plc (Ortho), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, has announced the pricing of its initial public offering of 76 million ordinary shares at US$17 per share. The gross proceeds raised from this offering are expected to be US$1,292 million. Ortho's ordinary shares are expected to begin trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX," and the offering is expected to close on February 1, 2021, subject to customary closing conditions.

Designed and developed with the clinical laboratory in mind, MAS third-party, multi-analyte quality controls are ready to use, requiring no reconstitution, saving you time and money. With unparalleled open vial stability, MAS Quality Controls for general chemistry and immunology ensure consistent and reliable results. Paired with the flexibility offered by Ortho VITROS Analyzers, clinical laboratories can maximize their productivity like never before.

QuidelOrtho aims to unite technologies and platforms to offer expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and point-of-care diagnostic offerings.

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest Diagnostics, the world's leading provider of diagnostic information services, to expand COVID-19 antibody testing to more than 20 Quest laboratories across the U.S.

Ortho Clinical Diagnostics, a Carlyle-backed global provider of in vitro diagnostic products, announced terms for its IPO on Tuesday.

The Raritan, NJ-based company plans to raise $1.5 billion by offering 70 million shares at a price range of $20 to $23. At the midpoint of the proposed range, Ortho Clinical Diagnostics would command a fully diluted market value of $4.9 billion.

Acquired by The Carlyle Group in 2014, Ortho Clinical Diagnostics is a pure-play in vitro diagnostics (IVD) business that provides diagnostic testing solutions to the clinical laboratory and transfusion medicine communities, impacting approximately 800,000 patients every day.

Ortho Clinical Diagnostics was founded in 1939 and booked $1.7 billion in revenue for the 12 months ended September 30, 2020. It plans to list on the Nasdaq under the symbol OCDX. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays, Morgan Stanley, Citi, Credit Suisse, UBS Investment Bank, Evercore ISI and Piper Sandler are the joint bookrunners on the deal. It is expected to price during the week of January 25, 2021.

Despite being the fifth largest in vitro diagnostics (IVD) manufacturer in the world, OCD was performing below expectations. The company has had relatively slow growth and was not a market leader, according to Morningstar Analyst Debbie Wang, as reported by Reuters last year. She noted that these two facts made it difficult for the OCD unit to compete in clinical diagnostics.

Veteran pathologists and clinical laboratory managers remember that OCD was originally the Kodak Ektachem business owned by Eastman Kodak Co., of Rochester, New York. Ektachem analyzers used a dry chemistry technology. It was in 1994 when J&J acquired the Ektachem business from Kodak, the sales price was $1 billion. 2351a5e196